When Shire PLC created Shire Regenerative Medicine Inc. around the purchase of Advanced BioHealing Inc. (ABH) in 2011, it became the first major pharmaceutical or device company in some time to dedicate significant new resources to the regenerative medicine/cell therapy space. [See Deal] The field has been undergoing an evolution, gradually moving away from the notion of introducing cells into the body that would integrate and create new replacement tissue, directly restoring function, and toward using cells or biologics as a means of signaling the body to recruit new cells to the area to be treated.
There’s now a more nuanced notion around how to use cells – stem cells or other cell types like endothelial...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?